Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Letrozole in HER2+/ER+ Metastatic Breast Cancer
NCT04407988Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, HER2-positive breast cancer, estrogen receptor-positive breast cancer (ER+), sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancerHER2-positive breast cancerestrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT04407988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407988.